Emerging regulatory model of Ubiquitin-Specific Proteases 14 in cancer: from canonical oncogenesis to TME modulation, therapeutic resistance, and non-canonical activities
Authors:
Open Access
- 26 June 2026
- journal article
- review article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Abstract
Ubiquitin-Specific Protease 14 (USP14) is a proteasome-associated deubiquitinase historically viewed as a pro-tumorigenic driver of the ubiquitin-proteasome system (UPS) by stabilizing oncoproteins. Recent evidence expands this view, positioning USP14 as a central regulator that integrates tumor cell-intrinsic malignancy, tumor microenvironment (TME) remodeling, and resistance to multiple therapies. Importantly, USP14 exerts functions beyond canonical deubiquitination, including non-catalytic and scaffolding activities, and is subject to complex allosteric regulation. This review synthesizes emerging regulatory crosstalks that broaden the functional landscape of USP14 in cancer. We first outline the dynamic allosteric regulatory network of USP14 and its activation modes, emphasizing post-translational modifications (PTMs)-notably phosphorylation and lactylation-that modulate USP14 activity and connectivity beyond traditional links to cell cycle control and metabolism. We then consolidate the signaling frameworks through which USP14 contributes to resistance across therapeutic modalities, including targeted therapies, chemotherapy, radiotherapy, and immunotherapy, highlighting both shared and treatment-specific mechanisms. In parallel, we discuss context-dependent tumor-suppressive roles of USP14 and detail its non-catalytic scaffolding functions that reshape signaling outputs independent of enzymatic activity. Collectively, these classical and non-classical mechanisms depict USP14 as a systems-level coordinator of oncogenic signaling, adaptive stress responses, and microenvironmental interactions. By integrating catalytic and non-catalytic functions with PTM-driven allosteric regulation, we propose a unified regulatory model in which USP14 operates as a master node connecting malignancy, TME dynamics, and therapeutic resistance. This framework provides strategic guidance for developing next-generation allosteric inhibitors and combination strategies aimed at overcoming clinical drug resistance and exploiting context-specific vulnerabilities in USP14-regulated networks.Keywords
Funding Information
- National Natural Science Foundation of China (No.81803895)
- Natural Science Foundation of Shandong Province (ZR2021YQ57)
- Natural Science Foundation of Shandong Province (ZR2024MH266)
This publication has 140 references indexed in Scilit:
- Lactylation in cancer biology: Unlocking new avenues for research and therapyCancer Communications, 2025
- Dynamic networks connect the USP14 active site region with the proteasome interaction surfaceProtein Science, 2025
- Cuproplasia and cuproptosis, two sides of the coinCancer Communications, 2025
- Transient interdomain interactions in free USP14 shape its conformational ensembleProtein Science, 2024
- Deubiquitylating Enzymes in Cancer and ImmunityAdvanced Science, 2023
- A Ubiquitin‐Dependent Switch on MEF2D Senses Pro‐Metastatic Niche Signals to Facilitate Intrahepatic Metastasis of Liver CancerAdvanced Science, 2023
- In‐depth discovery of protein lactylation in hepatocellular carcinomaProteomics, 2023
- Targeted therapy for cisplatin‐resistant lung cancer via aptamer‐guided nano‐zinc carriers containing USP14 siRNAMedcomm, 2023
- Global profiling of protein lysine lactylation and potential target modified protein analysis in hepatocellular carcinomaProteomics, 2023
- Ubiquitin‐specific protease 14 is a new therapeutic target for the treatment of diseasesJournal of Cellular Physiology, 2020